Category : Healthcare and Pharmaceuticals | Published at : July-2022 | Delivery Format : PDF | Status: Published | Pages : 160
The global women’s health diagnostics market size is anticipated to hit around USD 77.2 billion by 2026, this market is anticipated to grow with 7.3% CAGR during the forecast time period.
Increasing occurrence of infectious diseases, for instance, urinary tract infection and hepatitis, among women is expected to boost the women’s health diagnostics market during the forecast period.
Market Dynamics
Rising adoption of point of-care diagnostics and developing occurrence of different chronic and lifestyle diseases are among the key components invigorating the development of the market. Other than this, presenting different mindfulness programs is likewise foreseen to work in support the market amid the conjecture time frame. For example, in 2014, the European Commission propelled joint activity for European Guide on Quality Improvement in Comprehensive Cancer Control.
Ladies' well being diagnostics is seeing high development because of expanded subsidizing from different associations. For example, in May 2015, Abcodia got subsidizing of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to dispatch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early recognition of ovarian malignant growth.
Market Insights
Early diagnosis of any medical problem with help of advanced and versatile mammography, for example, bosom MRI, ultrasound, and bone thickness testing, is basic. Advancements in therapeutic science offer rewarding chances to keep beware of ladies driven conditions that incorporate irresistible illnesses, osteoporosis, and bosom disease. This is evaluated to work for the market. As indicated by information distributed by National Center for Biotechnology Information (NCBI), ladies are 30.0% progressively inclined to be contaminated with HIV contrasted with men.
As indicated by National Institutes of Health (NIH), 40.0% of ladies contract somewhere around one UTI in their lifetime. It likewise expresses that ladies matured under 50 years are multiple times likelier than men to build up an UTI. In the U.S., ladies experiencing UTIs enlist 8.1 million visits to social insurance suppliers every year.
Market Segmentation
Market By Application
- Cancer
- Breast Cancer Testing
- Cervical Cancer Testing
- Ovarian Cancer Testing
- Infectious Disease Testing
- Osteoporosis Testing
- Pregnancy and Fertility Testing
- Prenatal Testing
Market By End-user
- Hospital and Diagnostics Centers
- Home
Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
Asia Pacific is anticipated to be the quickest developing district amid the estimate time frame. Healthcare infrastructure, rising mindfulness about ladies' health disorders, government activities, and expanded investment of ladies in workforce are a portion of the elements ready to decidedly impact the development of the provincial market.
In November 2016, the Indian government propelled Pradhan MantriSurakshitMatritvaAbhiyan (PMSMA) plan to give free wellbeing checkups to pregnant ladies. Under this plan, ladies would be tried for iron deficiency, high glucose (gestational diabetes), pulse, hormonal clutters, and approach free ultrasounds to follow wellbeing and advancement of child in the womb.
Market Participants
Women’s health diagnostics market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. The major players associated with women’s health diagnostics are the Abbott, BD, Siemens Healthcare Private Limited, Koninklijke Philips N.V., GE Healthcare, Hologic, Inc., F. Hoffmann-La Roche Ltd. and bioMérieux SA.
